Genitourinary System Carcinoma

Ovarian clear cell carcinoma is a relatively chemotherapy-refractory ovarian cancer subtype with a comparatively stable genome and a well-recognized association with endometriosis, but the somatic alt… (full text at CIViC)

PMID 20942669 · Wiegand et al., 2010 · Open in CIViC

This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed. These samples were then divided according to ARID1A expression after immunohis… (full text at CIViC)

PMID 25628030 · Park et al., 2015 · Open in CIViC

LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion.

PMID 12517791 · Hara et al., 2003 · Open in CIViC

Argani, et al. (2001) included eight morphologically distinctive renal cell carcinomas with the t(X;17) translocation as seen in alveolar soft part sarcoma (ASPS), with the distinction that the t(X;17… (full text at CIViC)

PMID 28766250 · Ju et al., 2018 · Open in CIViC

Argani, et al. (2001) included eight morphologically distinctive renal cell carcinomas with the t(X;17) translocation as seen in alveolar soft part sarcoma (ASPS), with the distinction that the t(X;17… (full text at CIViC)

PMID 11438465 · Argani et al., 2001 · Open in CIViC

This study (PMID 32343890) by de Bono et al, is a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) w… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In the exploratory ATM subgroup of the randomized phase III TRITON3 trial, 103 patients with metastatic castration-resistant prostate cancer harboring germline or somatic deleterious ATM alterations w… (full text at CIViC)

PMID 36795891 · Fizazi et al., 2023 · Open in CIViC

In the phase 3 TALAPRO-2 trial 805 patients with castration-resistant prostate cancer were enrolled and randomized to talazoparib or placebo plus enzalutamide treatment. Patients were tested for homol… (full text at CIViC)

PMID 37285865 · Agarwal et al., 2023 · Open in CIViC

In patients with ovarian carcinomas, those with Aurora kinase A expression (as measured by immunohistochemistry) had increased progression-free and overall survival compared to those without expressio… (full text at CIViC)

PMID 19157502 · Mendiola et al., 2009 · Open in CIViC

In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol.

PMID 12559175 · Anand et al., 2003 · Open in CIViC

A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P = 0.001; HR 0.14) and platinum therapy resistance … (full text at CIViC)

PMID 27209210 · Mignogna et al., 2016 · Open in CIViC

438 patients with non-metastatic clear-cell renal carcinoma were were retrospectively analysed for B4GALT1 expression via IHC. High B4GALT1 expression was associated with poor overall survival (P<0.00… (full text at CIViC)

PMID 27092876 · Xie et al., 2016 · Open in CIViC

BAP1 loss sensitized cells to the PARP inhibitor olaparib. In addition, BAP1-deficient cells were more sensitive to ionizing radiation.

PMID 22683710 · Peña-Llopis et al., 2012 · Open in CIViC

In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type.

PMID 23797736 · Sato et al., 2013 · Open in CIViC

In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type.

PMID 23797736 · Sato et al., 2013 · Open in CIViC

A patient with Clear cell renal cell carcinoma previously treated with sorafenib, axitinib, and everolimus was found to harbor a BAP1 frameshift mutation described as c.799_800del (p.Q267fs). Based o… (full text at CIViC)

PMID 35875073 · Lian et al., 2022 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcri… (full text at CIViC)

PMID 26324360 · Grisham et al., 2015 · Open in CIViC

A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard ch… (full text at CIViC)

PMID 26490654 · Combe et al., 2015 · Open in CIViC

AURELIA trial indicated substantial improvement in progression-free survival and overall survival in ovarian cancer patients with PD-L1 positive expression in response to bevacizumab plus single regim… (full text at CIViC)

PMID 31105696 · Zhang et al., 2019 · Open in CIViC

In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival.

PMID 22274685 · Bolton et al., 2012 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC)

PMID 27717299 · Mirza et al., 2016 · Open in CIViC

In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC)

PMID 27717299 · Mirza et al., 2016 · Open in CIViC

In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines e… (full text at CIViC)

PMID 23415752 · Stordal et al., 2013 · Open in CIViC

In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival.

PMID 22274685 · Bolton et al., 2012 · Open in CIViC

In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous … (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

Renal cell carcinoma (RCC) remains an intractable genitourinary malignancy. Resistance to chemotherapy or targeted therapies in RCC is presumably due to the complicated underlying molecular mechanisms… (full text at CIViC)

PMID 28391274 · Wu et al., 2017 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

28 renal cell carcinoma cell lines were tested for sensitivity to CDK4/6 inhibitor Palbociclib (PD0332991). 19 were reported sensitive, and 9 resistant. 15 of the 28 cell lines had high levels of Cycl… (full text at CIViC)

PMID 23898052 · Logan et al., 2013 · Open in CIViC

In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival.

PMID 20336784 · Nakayama et al., 2010 · Open in CIViC

A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors

PMID 27663592 · Au-Yeung et al., 2017 · Open in CIViC